Jepajinjung 25 mg (Empagliflozin)

Adult dose

The recommended dose of this medication is 10 mg once daily for monotherapy and adjunct therapy with other glucose-lowering agents such as insulin. If good tolerance is observed and further blood sugar control is needed, the dose can be increased to 25 mg once daily. This medication can be taken regardless of meals, and the tablets should be swallowed whole. If a dose is missed, take it as soon as remembered, but do not take double the dose in one day.

This medication should not be used in patients with allergies to the active ingredient or any of its components. Patients with type 1 diabetes or diabetic ketoacidosis should not take this medication. Patients with very poor kidney function, specifically those with a glomerular filtration rate below 30 mL/min/1.73m2, end-stage renal disease, or those undergoing dialysis should not use this medication. This medication contains lactose and should not be administered to patients with genetic issues such as lactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. Caution should be exercised in administering this medication to patients with slight kidney impairment, and dosage adjustment or discontinuation may be necessary if kidney function continues to deteriorate. Patients with mild to moderate heart failure should use this medication cautiously, and it is not recommended for severe heart failure patients. When taken with insulin or sulfonylureas, the risk of hypoglycemia may increase, and a reduction in the doses of these medications may be necessary. Patients may experience adverse reactions such as hypoglycemia, genital infections, urinary tract infections, increased urination, reduced fluid volume, increased serum creatinine, and others during the use of this medication; therefore, caution is required. A serious metabolic anomaly, known as ketoacidosis, may occur; thus, immediate consultation with medical personnel is necessary in case of symptoms. Elderly patients or those at risk of fluid volume loss should carefully monitor their hydration status due to the potential for dehydration and hypotension. This medication may increase the risk of genital fungal infections, and appropriate treatment is needed if infection symptoms appear. Caution is required during driving or operating machinery due to the risk of hypoglycemia, especially when used in combination with insulin. Pregnant women should avoid using this medication, and it should be discontinued immediately upon confirmation of pregnancy. It is recommended to suspend breastfeeding when taking this medication. Safety and efficacy in children have not been established, so it is not used in those under the age of 18. No specific toxicity has been reported in cases of overdose; however, appropriate treatment may be necessary based on the clinical condition. This medication should be stored out of the reach of children and not transferred to other containers. Regular kidney function tests should be conducted during treatment with this medication, and caution should be exercised regarding interactions with other medications.

Serious side effects

• Urticaria
• angioedema
• ketoacidosis
• urinary sepsis
• pyelonephritis
• perineal necrosis

Mild side effects

• Hypoglycemia
• vulvovaginal candidiasis
• vulvitis
• balanitis
• and other genital infections
• increased urination
• urinary difficulty
• rash
• itching
• increased serum lipids

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is best to maintain a storage temperature between 1 degree and 30 degrees Celsius. Proper storage will help preserve the efficacy of the medication for a longer period.

Appearance

Pale yellow, biconvex, oval film-coated tablet

Package unit

Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle